Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In a ceremony held last month, the 2024 Louisa Gross Horwitz Prize was awarded to Wesley Sundquist, PhD, Leo T. and Barbara K ...
NORTHAMPTON, MA / ACCESS Newswire / March 14, 2025 / In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her ...
Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...
6h
Barchart on MSNGilead Sciences - Leader in HIV MedicinesYour FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
14h
MedPage Today on MSNOnce-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Gilead Sciences's GILD short percent of float has risen 6.47% since its last report. The company recently reported that it ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results